Jounce therapeutics, inc. (JNCE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities:
Net loss

-26,443

-22,667

98,860

-6,993

-12,377

-2,040

-7,637

-4,674

-13,028

-9,364

-4,084

-3,380

385

5,466

4,070

-12,349

-10,890

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,618

2,265

2,289

2,513

2,542

2,444

2,335

2,360

2,268

1,312

1,074

1,036

1,353

1,269

2,625

655

440

Depreciation expense

938

994

983

963

960

933

959

961

947

900

909

1,625

966

545

487

465

447

Net amortization of premiums and discounts on investments

84

233

364

409

474

498

471

307

-169

-306

-309

-278

-279

-237

-90

0

0

Other non-cash items

-19

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

14

-

-

-

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

543

-399

-75

-747

2,596

-271

-13

-1,076

487

11,475

5,104

-800

1,637

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

474

Other non-current assets

-18

146

-46

525

103

50

-19

14

-45

-39

218

-52

139

1,339

290

-1,094

-8

Accounts payable

1,407

-1,111

812

-1,416

771

331

30

-2,088

2,289

-934

984

-820

1,143

623

-235

-898

198

Accrued expenses and other current liabilities

-1,457

1,953

-305

1,276

-941

-782

760

747

-2,168

2,049

285

2,098

-312

1,316

482

174

-1,019

Deferred revenue—related party

0

0

-69,445

-17,446

-10,981

-20,100

-14,528

-19,378

-11,195

-

-

-

-

-

-

-

-

Other liabilities

-19

-4

-5

-3

16

22

22

22

41

-

-

-

-

-

-

-

-

Deferred revenuerelated party

-

-

-

-

-

-

-

-

-

-

-

-

-20,290

-20,288

208,092

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

51

50

-1,084

827

687

-165

-162

-168

Net cash used in operating activities

-23,546

-18,599

32,946

-21,293

-23,183

-19,438

-18,498

-4,558

-21,119

-24,171

-24,812

-24,566

-17,439

-11,873

214,837

-11,818

-11,458

Investing activities:
Purchases of investments

19,856

41,004

58,515

27,461

62,019

58,219

66,810

126,887

1,002

34,988

11,623

25,541

107,722

31,012

182,274

0

0

Proceeds from maturities of investments

63,650

42,705

54,153

47,000

77,508

72,267

88,514

55,100

120,813

55,087

23,167

29,518

33,550

-

-

-

-

Proceeds from sales of investments

-

-

-

-

-

-

-

-

-

-

-

-

8,396

-

-

-

-

Sales and maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchases of property and equipment

50

0

423

453

109

234

166

729

230

1,414

1,731

4,885

7,077

968

620

384

250

Net cash provided by investing activities

43,744

1,701

-4,785

19,086

15,380

13,814

21,538

-68,519

119,581

18,685

9,813

6,334

-72,853

-31,980

-182,894

-384

-250

Financing activities:
Proceeds from at the market offering, net of issuance costs

1,514

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from initial public offering of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

0

0

-318

107,326

0

0

0

0

Proceeds from exercise of stock options

38

92

247

29

69

247

134

381

784

-

151

41

109

-

4

24

18

Cash paid for issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,640

1,643

Net cash provided by financing activities

1,552

3,737

247

29

69

247

134

381

784

161

151

-277

107,435

-616

36,084

1,664

-1,625

Net increase (decrease) in cash, cash equivalents and restricted cash

21,750

-13,161

28,408

-2,178

-7,734

-5,377

3,174

-72,696

99,246

-5,325

-14,848

-18,509

17,143

-

-

-

-

Non-cash investing and financing activities:
Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-44,469

68,027

-10,538

-13,333

Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses

0

-

-

-20

20

-

-

-468

578

-596

-1

-1,596

2,363

1,666

30

15

159

Issuance costs in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

232

730

93

-81

108

Supplemental cash flow information:
Cash paid for lease liabilities

1,090

1,070

1,070

1,070

1,060

0

0

0

0

-

-

-

-

-

-

-

-